Romeo Mandanas, MD
Hematology & Oncology · Oklahoma City, OKNPI 1114974466
Payments from drug & device makers
Across 351 payments — averaging $1193.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$145K
- Exelixis Inc.$61K
- Bristol Myers Squibb$45K
- Johnson & Johnson$38K
- Novartis$28K
- Morphosys AG$17K
- plus $85K from 34 others
What the payments were for
- Consulting fees$42,62027%
- Speaking & faculty fees$94,82759%
- Travel & lodging$15,0659%
- Food & beverage$5,6354%
- Education$6540%
- Other$1,2801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 63 | $144,942 |
| Exelixis Inc. | 12 | $60,512 |
| Bristol Myers Squibb | 39 | $45,439 |
| Johnson & Johnson | 34 | $38,147 |
| Novartis | 41 | $28,056 |
| Morphosys AG | 2 | $16,675 |
| AstraZeneca(2 entities) | 25 | $15,675 |
| Astrazeneca UK Limited | 2 | $15,288 |
| AbbVie | 5 | $9,869 |
| Mirati Therapeutics, Inc. | 7 | $7,295 |
| E.r. Squibb & Sons, L.L.C. | 9 | $6,549 |
| Amgen | 5 | $5,264 |
| Seagen Inc. | 14 | $4,631 |
| Genentech, Inc. | 1 | $3,329 |
| Sanofi | 5 | $2,667 |
| Karyopharm Therapeutics Inc. | 4 | $2,601 |
| Bayer | 5 | $2,572 |
| Array Biopharma Inc | 2 | $2,422 |
| TG Therapeutics, Inc. | 1 | $2,025 |
| Morphosys, US Inc. | 1 | $2,000 |
| Pfizer | 38 | $717 |
| Janssen Scientific Affairs, LLC | 3 | $709 |
| GSK | 1 | $550 |
| Galvanize Therapeutics, Inc | 1 | $177 |
| Merck | 5 | $156 |
| Blueprint Medicines Corporation | 2 | $155 |
| Astellas Pharma US Inc | 5 | $124 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $42 |
| Caris MPI, Inc. | 1 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $41 |
| Genmab U.S., Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Clovis Oncology, Inc. | 2 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$418,911 in reported general payments places this provider in the 90th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 46 | $639,900 |
| RevlimidLenalidomide | 32 | $570,212 |
| VenclextaVenetoclax | 43 | $413,753 |
| TagrissoOsimertinib Mesylate | 24 | $400,718 |
| ImbruvicaIbrutinib | 12 | $392,695 |
| BrukinsaZanubrutinib | 25 | $302,596 |
| TasignaNilotinib Hcl | 14 | $269,605 |
| XalkoriCrizotinib | 14 | $208,986 |
| PromactaEltrombopag Olamine | 11 | $127,580 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $86,113 |
| EliquisApixaban | 64 | $48,768 |
| Imatinib Mesylate | 24 | $45,094 |
| Xtampza ErOxycodone Myristate | 13 | $8,603 |
| Enoxaparin Sodium | 12 | $4,847 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $2,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $124 | $639,90046 claims |
| Bristol Myers SquibbRevlimid | $45,439 | $570,21232 claims |
| AbbVieVenclexta | $9,869 | $413,75343 claims |
| AstraZenecaTagrisso | $15,675 | $400,71824 claims |
| NovartisTasigna, Promacta | $28,056 | $397,18525 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $41 | $392,69512 claims |
| PfizerXalkori, Eliquis | $717 | $257,75478 claims |
| Lilly USA, LLCOlanzapine | $42 | $42416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Carrie YuenOklahoma City$564K
- David LamOklahoma City$445K
- Carla KurkjianOklahoma City$310K
- Sonia VargheseOklahoma City$295K
- Mohammad RazaqOklahoma City$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.